Human Muscarinic Acetylcholine Receptor M5 (CHRM5) Peptide (OVA)

Product specifications

Proteins and Peptides

Muscarinic Acetylcholine Receptor M5 (CHRM5)

Human

OVA

Concentration: Prior to lyophilization: 200 µg/ml
Sequence Fragment: His7-Arg24

Synthetic

> 90%

100 µg

200 µg

500 µg

1 mg

5 mg

Lyophilized To keep the original salt concentration, we recommend reconstituting to the original concentration prior to lyophilization (see Concentration) in ddH2O. If a lower concentration is required, dilute in PBS, pH 7.4. If a higher concentration is required, the product can be reconstituted directly in PBS, pH 7.4, though please note that this will change the overall salt concentration. The stock concentration should be between 0.1-1.0 mg/ml. Do not vortex.

WB, SDS-PAGE

Prior to lyophilization: PBS, pH 7.4.

Shipped within 5-7 working days.

Store at 2-8 °C for up to one month. Store at -80 °C for up to one year. Avoid repeated freeze/thaw cycles.

No

P08912

1133

118496

CHRM5,M5R,cholinergic receptor, muscarinic 5,cholinergic receptor,M5 receptor,HM5

Protein CHRM5

RUO

This product is for research use only.   Not for human consumption, cosmetic, therapeutic or diagnostic use.

Descripción

CHRM5 encodes the muscarinic acetylcholine receptor M5, the least abundant subtype of the muscarinic receptor family. Unlike CHRM4, CHRM5 primarily couples to Gq/11 proteins, activating phospholipase C (PLC) and increasing the production of inositol triphosphate (IP3) and diacylglycerol (DAG). This cascade results in an elevation of intracellular calcium ion levels and downstream activation of protein kinase C (PKC). CHRM5 is expressed in limited regions of the central nervous system, including the midbrain dopamine neurons, hippocampus, and vascular endothelial cells. Its activation plays a key role in cerebral blood flow regulation, dopamine release, and synaptic plasticity, which are critical for processes such as learning, memory formation, and reward processing. CHRM5 is also implicated in addiction and substance abuse disorders, as its activation enhances dopamine release in the brain's reward centers. CHRM5-selective agonists are of therapeutic interest for improving cognitive function in diseases like Alzheimer's disease and vascular dementia, while antagonists could be useful for modulating excessive cholinergic activity. Additionally, CHRM5 is explored for its role in promoting vasodilation of cerebral arteries, which may have implications in treating stroke or ischemic conditions. Genetic variants of CHRM5 are associated with susceptibility to neurodegenerative diseases, emphasizing its role as a critical therapeutic target in neurology and psychiatry.

Related Products

Muscarinic Acetylcholine Receptor M5 (CHRM5) Antibody

CHRM5 Antibody is a Rabbit Polyclonal antibody against CHRM5. The muscarinic cholinergic receptors belong to a larger family of G protein-coupled receptors. The functional diversity of these receptors is defined by the binding of acetylcholine and includes cellular responses such as adenylate cyclase inhibition, phosphoinositide degeneration, and potassium channel mediation. Muscarinic receptors influence many effects of acetylcholine in the central and peripheral nervous system. The clinical implications of this receptor are unknown; however, stimulation of this receptor is known to increase cyclic AMP levels.

Ver Producto

Muscarinic Acetylcholine Receptor M5 (CHRM5) Antibody

CHRM5 Antibody is a Rabbit Polyclonal against CHRM5.

Ver Producto

Muscarinic Acetylcholine Receptor M5 (CHRM5) Antibody

CHRM5 Antibody is a Rabbit Polyclonal against CHRM5.

Ver Producto